# Gastroesophageal Reflux and GERD in Infants

## Overview

Gastroesophageal reflux (GER) is the physiologic passage of gastric contents into the esophagus and is extremely common in infants. It peaks in prevalence at 4-5 months of age, when approximately 67% of infants spit up, and resolves in 95% by 12-14 months. Gastroesophageal reflux disease (GERD) is defined as GER that causes troublesome symptoms or complications. The central clinical challenge is distinguishing the "happy spitter" from an infant with true GERD requiring intervention. PPIs are vastly overprescribed in infants, and most infant reflux does not require acid suppression.

## Pathophysiology

The lower esophageal sphincter (LES) is immature in infants, with frequent transient LES relaxations (TLESRs). A liquid diet, supine positioning, small stomach capacity, and frequent feeding all promote reflux. As the infant matures, LES tone improves, upright posture increases, and solid foods are introduced, causing reflux to resolve naturally. In true GERD, acid and pepsin exposure causes esophageal mucosal injury, leading to esophagitis, feeding aversion, and respiratory complications.

## Physiologic GER ("Happy Spitter")

| Feature | Physiologic GER ("Happy Spitter") | GERD |
|---------|----------------------------------|------|
| Regurgitation | Effortless, during/after feeds | May be forceful or associated with distress |
| Weight gain | Normal | Poor weight gain or weight loss |
| Feeding behavior | Normal, eager to feed | Feeding refusal, arching (Sandifer syndrome) |
| Irritability | Normal infant behavior | Persistent, especially with feeds |
| Respiratory symptoms | None | Recurrent wheeze, cough, aspiration pneumonia |
| Hematemesis/blood in stool | Absent | May be present (esophagitis) |
| Workup needed | None | Clinical diagnosis; testing for atypical cases |
| Treatment | Reassurance only | Stepwise: conservative → CMPA trial → PPI if esophagitis |
| Natural history | Resolves by 12-14 months in 95% | May require intervention |

The "happy spitter" presents with effortless regurgitation or spitting up, typically during or shortly after feeds. Weight gain is normal, feeding behavior is normal, and the infant is content between episodes. There are no respiratory symptoms, no feeding refusal, and no irritability beyond normal infant behavior. No workup is needed, no treatment is needed, and reassurance with anticipatory guidance is the entire management.

## GERD: When Reflux Becomes Disease

### Symptoms Suggesting GERD

Feeding refusal or arching during feeds (known as Sandifer syndrome, a dystonic posturing pattern) is a key indicator. Poor weight gain or weight loss, persistent irritability especially with feeds, hematemesis or occult blood in stool from esophagitis, and recurrent pneumonia or chronic cough from aspiration all point toward GERD. Apnea or ALTE/BRUE has a controversial association, as reflux is rarely proven as the cause. Stridor or recurrent wheezing not explained by other causes may also suggest GERD.

### Differential Diagnosis (Not Everything is Reflux)

Cow's milk protein allergy or intolerance is the most important mimicker. Pyloric stenosis presents with projectile vomiting at 3-6 weeks of age. Malrotation with intermittent volvulus causes bilious vomiting and is a surgical emergency. Eosinophilic esophagitis, increased intracranial pressure (bulging fontanelle, macrocephaly), metabolic disorders (urea cycle defects, organic acidemias), and urinary tract infections or other occult infections should all be considered.

<image>Comparison of physiologic GER versus GERD in infants showing the "happy spitter" with normal growth and no complications alongside GERD presentations including feeding refusal, weight loss, esophagitis, Sandifer syndrome (dystonic neck posturing), and respiratory complications</image>

## Diagnostic Evaluation

GERD in infants is a clinical diagnosis, and routine testing is not recommended for typical presentations. Testing is reserved for atypical presentations or when complications are suspected.

### Available Tests (When Indicated)

An upper GI series is not a test for reflux, since all infants reflux during the study. Its purpose is to rule out anatomic abnormalities such as malrotation, stricture, or web. pH-impedance monitoring (pH-MII) is a 24-hour study that measures both acid and non-acid reflux episodes and is useful for correlating symptoms with reflux events, particularly in atypical presentations. Esophageal endoscopy with biopsy is indicated for suspected esophagitis, eosinophilic esophagitis, or stricture. Nuclear medicine milk scans assess gastric emptying and aspiration but have limited clinical utility. An empiric trial of cow's milk protein elimination is recommended before acid suppression when CMPA is in the differential, with a 2-4 week trial of extensively hydrolyzed or amino acid formula.

## Management

### Conservative Measures (First-Line for All)

Feeding modifications include smaller, more frequent feeds, adequate burping, and thickened feeds (1 tablespoon rice cereal per ounce of formula or commercially thickened formulas). Thickened feeds reduce visible regurgitation but do not reduce measurable reflux episodes. For positional therapy, upright positioning for 20-30 minutes after feeds is helpful. Prone or lateral positioning for sleep must not be recommended, as supine positioning remains mandatory for safe sleep regardless of reflux. Elevating the head of the crib is also not recommended because the infant slides down, there is no proven benefit, and it poses an aspiration risk. A cow's milk protein elimination trial (2-4 week trial of extensively hydrolyzed formula such as Alimentum or Nutramigen, or amino acid formula such as EleCare, with maternal dairy elimination if breastfeeding) should be attempted before acid suppression. Reassurance and education about the natural history of resolution by 12 months is the most important intervention.

### Pharmacotherapy

#### Acid Suppression (When Truly Indicated)

Proton pump inhibitors (lansoprazole, omeprazole, esomeprazole) are only indicated for documented or strongly suspected erosive esophagitis. They are not indicated for a "fussy baby" or uncomplicated spitting up. Trial duration is 4-8 weeks, followed by an attempt to wean. Adverse effects include increased risk of C. difficile infection, community-acquired pneumonia, gastric polyps, potential bone density effects, and hypomagnesemia. H2 receptor antagonists (famotidine) are less potent than PPIs and sometimes used as an alternative; ranitidine was removed from the market in 2020 due to NDMA contamination. Crucially, PPIs have not been shown to reduce crying, irritability, or visible regurgitation in infants; randomized trials demonstrate no difference from placebo for these symptoms.

#### Prokinetics

Prokinetics are not recommended in infants due to adverse effects and lack of proven efficacy. Metoclopramide carries a risk of tardive dyskinesia and dystonic reactions with an FDA black box warning. Erythromycin has limited evidence and carries a risk of pyloric stenosis in infants younger than 6 weeks.

### Surgical Intervention

Nissen fundoplication is reserved for severe, medically refractory GERD with life-threatening complications. Indications include recurrent aspiration pneumonia, severe esophagitis unresponsive to medical therapy, and GERD in neurologically impaired children requiring gastrostomy. Complications include wrap failure, gas-bloat syndrome, dumping syndrome, and dysphagia.

<image>Stepwise management approach for infant GERD showing progression from conservative measures (feeding modifications, positioning, reassurance) to cow's milk protein elimination trial, then acid suppression with PPI for confirmed esophagitis, and finally surgical referral for refractory cases, with decision points and red flags at each level</image>

## Special Populations

### Preterm Infants

GER is nearly universal in preterm infants. The association between reflux and apnea of prematurity is weak and often overstated. PPIs and H2RAs are frequently prescribed in NICUs without evidence of benefit and with potential harm, including increased risk of necrotizing enterocolitis, sepsis, and pneumonia.

### Neurologically Impaired Children

These children have a higher prevalence of true GERD due to hypotonia, supine positioning, delayed gastric emptying, and seizure medications. They often require long-term acid suppression. Gastrostomy with fundoplication may be needed for severe cases.

## Clinical Pearls

The "happy spitter" needs reassurance, not a PPI; if the infant is growing well and feeding comfortably, it is physiologic GER. Bilious (green) vomiting in any infant is malrotation with volvulus until proven otherwise and constitutes a surgical emergency. Cow's milk protein allergy should always be considered before starting acid suppression, as a 2-4 week elimination trial is both diagnostic and therapeutic. PPIs do not reduce infant crying or fussiness, as multiple randomized trials confirm; prescribing PPIs for "colic" exposes infants to unnecessary risk. Sandifer syndrome (episodic dystonic posturing of the head and neck) can be mistaken for seizures but is actually a manifestation of GERD-related esophagitis. When the diagnosis is uncertain, an upper GI series to exclude anatomic problems and a pH-impedance study to document reflux-symptom correlation are the most useful tests.

## Key Controversy: Overdiagnosis and Overtreatment of Infant GERD

PPIs are among the most overprescribed medications in pediatrics, especially in infants. Trials (Orenstein 2009, INFANT trial) show PPIs are no better than placebo for reducing crying and irritability. NASPGHAN/ESPGHAN guidelines explicitly state PPIs should not be used for uncomplicated infant reflux. The risks of PPIs in infants include increased C. difficile infection, community-acquired pneumonia, and possible effects on the gut microbiome and bone health. Drivers of overuse include parental anxiety, physician desire to "do something," and misleading pharmaceutical marketing. Solutions include parent education about natural history, watchful waiting, and structured follow-up visits.

<image>Evidence summary showing results of randomized controlled trials comparing PPIs versus placebo for infant irritability and crying, demonstrating no significant difference in outcomes, alongside a risk-benefit analysis of PPI use in infants including increased infection rates and microbiome alterations</image>

## References
- Rosen R, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines (NASPGHAN/ESPGHAN). J Pediatr Gastroenterol Nutr. 2018;66(3):516-554.
- Orenstein SR, et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of GERD. J Pediatr. 2009;154(4):514-520.
- Lightdale JR, Gremse DA. Gastroesophageal Reflux: Management Guidance for the Pediatrician (AAP Section on Gastroenterology). Pediatrics. 2013;131(5):e1684-e1695.
- Horvath A, et al. Thickened-Feed Interventions for Gastroesophageal Reflux in Infants. Cochrane Database Syst Rev. 2008;(4):CD003211.
- Vandenplas Y, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines. J Pediatr Gastroenterol Nutr. 2009;49(4):498-547.